Technology in Cancer Research & Treatment最新文献

{"title":"Risk Factors of Positive Endocervical Curettage and Predictive Model Construction Based on Primary Human Papillomavirus Screening.","authors":"Hangjing Gao, Guanxiang Huang, Binhua Dong, Ye Li, Hongning Cai, Xianqian Chen, Tingting Jiang, Kelvin Stefan Osafo, Dabin Liu, Jiancui Chen, Huihua Ge, Diling Pan, Huifeng Xue, Pengming Sun","doi":"10.1177/15330338241312573","DOIUrl":"10.1177/15330338241312573","url":null,"abstract":"<p><p>IntroductionThe utility and application of endocervical curettage (ECC) during colposcopy remain controversial. This study optimized ECC application for primary human papillomavirus (HPV) screening in patients with high-risk (HR)-HPV.MethodsThis retrospective study included patients with HR-HPV, who underwent subsequent cervical biopsy and ECC from January 1, 2014, to December 31, 2020. Logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). The prediction model was presented as a nomogram and evaluated for discrimination and calibration.ResultsThe additional detection rate of cervical intraepithelial neoplasia 2 + lesions with ECC was 2.0% (77/3887) in patients with HR-HPV. In multivariate risk factor analysis, HPV 16 infection presented a high risk of positive ECC, followed by HPV 33, HPV 58, and HPV 31. Irrespective of the abnormal cytopathological results, positive ECC was significantly increased (all <i>P</i> < .001). Females with acetowhite changes on colposcopy, transformation zone (TZ) type II, TZ type III, colposcopic impression of high-grade squamous intraepithelial lesion, or cancer were at a high risk of positive ECC. The final prediction model included significant variables from risk factor analysis, and had excellent calibration and classification capabilities, with an area under the receiver operating curve of 0.902 (95% CI, 0.881-0.922). Additionally, calibration analysis suggested consistency.ConclusionAs the additional detection value of ECC is limited. A satisfactory prediction model was designed to optimize ECC application in patients with HR-HPV infection.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241312573"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics Analysis of Histone-related Genes in Osteosarcoma: A Multidimensional Integrated Study Revealing Drug Sensitivity and Immune Microenvironment Characteristics.","authors":"Yang Yang, Xinqiao Tang, Zhong Liu","doi":"10.1177/15330338251336275","DOIUrl":"https://doi.org/10.1177/15330338251336275","url":null,"abstract":"<p><p>IntroductionOsteosarcoma (OS) is a highly aggressive primary bone malignancy with poor prognosis. Histone modifications play crucial roles in tumor progression, but their systematic investigation in OS remains unexplored.MethodsThis study integrated single-cell RNA sequencing data and large-scale clinical information to systematically analyze the spatial heterogeneity of histone modifications in OS and their clinical significance. We employed Seurat for single-cell data analysis, CellChat for cell-cell communication network analysis, and LASSO Cox regression to construct a prognostic model. Additionally, we conducted functional enrichment analysis, immune characteristics analysis, and drug sensitivity prediction.ResultsWe identified five major cell types in the OS microenvironment and discovered significant differences in histone modification levels among different cell types, with osteosarcoma cells and endothelial cells exhibiting higher modification levels. Cell-cell communication network analysis revealed the importance of signaling pathways such as SPP1, CypA, MIF, IGFBP, and VEGF in OS. Based on nine histone modification-related genes, we constructed an efficient prognostic model (AUC values of 0.713, 0.845, and 0.888 for 1-, 3-, and 5-year predictions, respectively), which was validated in an external cohort (AUC = 0.808). Immune microenvironment analysis showed significantly higher proportions of CD8+ T cells and Treg cells in the low-risk group. Drug sensitivity analysis revealed that the low-risk group was more sensitive to Imatinib, Rapamycin, and Sunitinib, while the high-risk group was more sensitive to MAPK pathway inhibitors.ConclusionThis study systematically revealed the spatial heterogeneity of histone modifications in OS and their clinical significance for the first time, proposing an \"epigenetic-immune\" regulatory network hypothesis and developing a histone modification-based prognostic model. Our proposed \"epigenetic-guided personalized medication strategy\" provides new insights for precision treatment of OS, potentially significantly improving patient prognosis.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336275"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges.","authors":"Bo Pei, Shixuan Peng, Weiwei Chen, Lin Lai, Fuxiang Zhou","doi":"10.1177/15330338251334209","DOIUrl":"https://doi.org/10.1177/15330338251334209","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a formidable global health challenge, with the majority of patients exhibiting microsatellite stable (MSS) and proficient mismatch repair (pMMR) tumors that are largely unresponsive to immune checkpoint inhibitors (ICIs). The management of MSS/pMMR CRC remains a clinical challenge due to the intrinsic resistance to ICIs. The innovative strategy of combining cetuximab, an EGFR-targeting monoclonal antibody with immunomodulatory properties, offers a promising strategy to enhance the immunotherapeutic response in MSS/pMMR CRC. This combination therapy is rooted in the complementary therapeutic mechanisms of cetuximab and ICIs, which may synergistically improve overall response rates and durability of response. Although some preclinical and clinical data have suggested additional promising results, there are still some challenges and questions that need to be addressed. Further large-scale, randomized, phase III clinical trials are required to confirm the efficacy and safety of this combination therapy. The ongoing clinical trials evaluating the safety and efficacy of cetuximab-ICI combinations are eagerly anticipated to pave the way for a new era in personalized immunotherapy for MSS/pMMR CRC.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251334209"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gut Microbiome and Its Multifaceted Role in Cancer Metabolism, Initiation, and Progression: Insights and Therapeutic Implications.","authors":"Kai Xu, Zainab Motiwala, Irene Corona-Avila, Dhruvi Makhanasa, Leen Alkahalifeh, Md Wasim Khan","doi":"10.1177/15330338251331960","DOIUrl":"https://doi.org/10.1177/15330338251331960","url":null,"abstract":"<p><p>This review summarizes the intricate relationship between the microbiome and cancer initiation and development. Microbiome alterations impact metabolic pathways, immune responses, and gene expression, which can accelerate or mitigate cancer progression. We examine how dysbiosis affects tumor growth, metastasis, and treatment resistance. Additionally, we discuss the potential of microbiome-targeted therapies, such as probiotics and fecal microbiota transplants, to modulate cancer metabolism. These interventions offer the possibility of reversing or controlling cancer progression, enhancing the efficacy of traditional treatments like chemotherapy and immunotherapy. Despite promising developments, challenges remain in identifying key microbial species and pathways and validating microbiome-targeted therapies through large-scale clinical trials. Nonetheless, the intersection of microbiome research and cancer initiation and development presents an exciting frontier for innovative therapies. This review offers a fresh perspective on cancer initiation and development by integrating microbiome insights, highlighting the potential for interdisciplinary research to enhance our understanding of cancer progression and treatment strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251331960"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study.","authors":"Pingchuan Li, Lineng Wei, Yinan Ji, Huawei Yang","doi":"10.1177/15330338251341195","DOIUrl":"https://doi.org/10.1177/15330338251341195","url":null,"abstract":"<p><p>IntroductionThe role of radiotherapy (RT) in de novo metastatic breast cancer (dnMBC) patients undergoing surgery remains controversial due to limited evidence. This study aimed to evaluate the impact of postoperative radiotherapy on survival outcomes in this population.Materials and methodsWe retrospectively analyzed 102 dnMBC patients who underwent surgery at a provincial cancer hospital. Patients were grouped based on whether they received postoperative RT. Baseline characteristics were compared using the chi-square test. Kaplan-Meier analysis and Cox proportional hazards models were used to assess the prognostic impact of postoperative radiotherapy on local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS).ResultsKM survival analysis showed that postoperative RT significantly improved LRFS (HR = 0.3634, 95%CI 0.1552-0.8508, <i>p</i> = .0197) and PFS (HR = 0.4903, 95%CI 0.3061-0.7855, <i>p</i> = .003) but had no significant effect on OS (HR = 0.7337, 95%CI 0.3514-1.508, <i>p</i> = .5395). Multivariate analysis identified postoperative RT as an independent protective factor for LRFS (HR = 0.265, 95%CI 0.088-0.795, <i>p</i> = .018) and PFS (HR = 0.525, 95%CI 0.313-0.882, <i>p</i> = .015). Subgroup analysis showed that for LRFS, RT had no significant interaction with different subgroup classification variables (all interaction <i>p</i> > .05). However, RT had a significant interaction with N stage for PFS (<i>p</i> = .016), specifically in N1-3 patients (HR = 0.384, 95% CI 0.221-0.668).ConclusionRT may improve disease control in selected dnMBC patients undergoing surgery, particularly those with lymph node metastasis. However, these findings still require further validation in larger, multicenter cohorts.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251341195"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Intertarget Distances on Single-Isocenter Radiotherapy Plans with jaw-Tracking and jaw-Fixed Techniques for Vertebral Metastases.","authors":"Ling Xu, Huarui Yin, Dewen Zhang, Wentong Qiu, Xianfang Yin, Kai Xie, Xinye Ni","doi":"10.1177/15330338251332386","DOIUrl":"https://doi.org/10.1177/15330338251332386","url":null,"abstract":"<p><p>IntroductionMultiple targets with varying distances are common in radiotherapy. Reducing treatment time in the plan design helps minimize patient movement and discomfort during the treatment process. This retrospective study aimed to investigate the impact of varying intertarget distances (ITDs) on the dosimetric differences and delivery efficiency of two single-isocenter techniques.MethodsITDs for 15 patients with dual-site vertebral metastases undergoing volume-modulated arc therapy (VMAT) were modified using Matlab 2019a. Distances of 2, 4, 6, 8, and 10 cm were considered. The VMAT plans were designed with a prescription dose of 40 Gy/20f on Infinity Linac and Monaco 5.40.01. Single-isocenter with jaw tracking (VMAT1) and fixed jaw (VMAT2) were compared in terms of dosimetry and delivery efficiency under different ITDs.ResultsResults showed that both VMAT plans exhibited dosimetric parameters meeting clinical requirements. The conformity index (CI) of VMAT1 plans was smaller than that of VMAT2 at ITD = 4, 6, and 8 cm (P = 0.007, 0.020, and 0.039, respectively), with no significant differences in other planning target volume dosimetry parameters. In terms of delivery efficiency, the treatment time of VMAT1 increased significantly when ITD > 2 cm compared with that at ITD = 2 cm (P = 0.000). Conversely, VMAT2 exhibited no significant change in treatment time at different ITDs (P = 0.073). For ITD = 2 cm, the treatment time of VMAT1 was shorter than that of VMAT2, with a median difference of 77 s. For ITD > 2 cm, the treatment time of VMAT2 was shorter than that of VMAT1, with a median difference ranging from 65 s to 121 s.ConclusionThe experimental results showed that the single-isocenter with jaw tracking is recommended in the planning design when ITDs are less than 2 cm. However, for ITDs greater than 2 cm, the single-isocenter with fixed jaw demonstrates high delivery efficiency.5075.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251332386"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Delivery System for Cancer Immunotherapy: Potential Roles, Challenge and Recent Advances.","authors":"Zi-Yue Lin, Qian Song, Kai Xu","doi":"10.1177/15330338251338390","DOIUrl":"https://doi.org/10.1177/15330338251338390","url":null,"abstract":"<p><p>Immunotherapy has emerged as a pivotal advancement in oncological therapeutics, representing a paradigm shift from conventional treatment modalities including surgery, radiotherapy, and chemotherapy. This innovative approach demonstrates considerable clinical potential through its capacity to enhance systemic anti-tumor responses via active or passive immunomodulation. Compared to traditional therapies, immunotherapy offers distinct advantages such as broad applicability, rapid therapeutic onset, and reduced adverse effects. However, critical challenges persist in clinical implementation, particularly concerning treatment safety and efficacy optimization. Current limitations, including drug off-target effects and biological delivery barriers, frequently result in suboptimal therapeutic outcomes and severe complications such as autoimmune disorders and nonspecific inflammation. Recently advancements in drug delivery systems (DDS) present transformative solutions to these challenges. Sophisticated DDS platforms enable precise spatiotemporal delivery of tumor antigens, immunotherapeutic agents, and immunostimulatory molecules, thereby achieving targeted modulation of diverse immune cell populations. This technological innovation not only enhances therapeutic efficacy but also significantly mitigates adverse reactions, while facilitating synergistic combinations with conventional cancer treatments. In this review, we outline the application of new drug delivery platforms in major malignancies (including but not limited to melanoma, non-small cell lung cancer, hormone receptor-positive breast cancer, and hepatocellular carcinoma). We further propose evidence-based optimization strategies for next-generation delivery platforms, aiming to bridge the gap between preclinical development and clinical implementation in cancer immunotherapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251338390"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated Relief: A Narrative Review of Two-Daily Fractions Palliative Radiotherapy in Advanced Cancer Care.","authors":"Erika Galietta, Costanza M Donati, Letizia Cavallini, Filippo Candoli, Francesco Cellini, Gabriella Macchia, Francesco Deodato, A F M Kamal Uddin, Mostafa A Sumon, Tigeneh Wondemagegnehu, Biniyam Tefera Deressa, Milly Buwenge, Alessio G Morganti, Savino Cilla","doi":"10.1177/15330338241293174","DOIUrl":"10.1177/15330338241293174","url":null,"abstract":"<p><p>AimsThis review aims to synthesize the existing literature on palliative radiotherapy (RT) delivered in two daily fractions for patients with advanced cancer, focusing on its impact on symptom alleviation, treatment tolerance, and the implications for clinical practice and future research.MethodsAn international team conducted this narrative review, adhering to SANRA guidelines. Studies published in English on palliative RT delivered in two daily fractions were selected without date restrictions. The literature search, using a combination of specific key terms, led to a comprehensive examination of relevant studies. Data on study objectives, treatment approaches, palliative effectiveness, and toxicity were extracted and qualitatively analyzed.ResultsThe review included 29 publications, showing consistent efficacy in symptom reduction (63.0%-100% palliative response rate) and general tolerability across various cancer types. These studies highlighted the potential radiobiological advantages and practicality of accelerated multi-fractionated regimens, which provide rapid tumor response with reduced late toxicity risks. Furthermore, the logistical benefits of such treatments, including shorter hospital stays and minimized travel requirements, were noted as particularly valuable during challenging times such as recent pandemics.ConclusionsThe evidence supports the integration of evidence-based, accelerated-hypofractionated RT into palliative care strategies, ensuring effective symptom management with minimal patient burden. Future research should focus on comparative studies on single versus multiple-cycle treatments, optimal intervals between treatment cycles, and the integration of advanced RT techniques.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241293174"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thanks to Reviewers.","authors":"","doi":"10.1177/15330338251321159","DOIUrl":"https://doi.org/10.1177/15330338251321159","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321159"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CENPF as a Potential Biomarker Associated with the Immune Microenvironment of Renal Cancer.","authors":"Meilin Chen, Xiuxin Tang, YanPing Liang, Tangdang Ding, Meifang He, Dong Wang, Ruizhi Wang","doi":"10.1177/15330338251330791","DOIUrl":"10.1177/15330338251330791","url":null,"abstract":"<p><p>IntroductionRenal cancer, particularly Kidney Renal Clear Cell Carcinoma (KIRC), remains a major clinical challenge due to its aggressive nature and poor prognosis. Identifying reliable biomarkers for tumor progression and survival is critical for improving patient outcomes. This study aimed to investigate the role of Centromere Protein F (CENPF) as a potential prognostic biomarker for renal cancer.MethodData from the TCGA database, including Kidney Chromophobe (KICH), Kidney Renal Papillary Cell Carcinoma (KIRP), and KIRC, were analyzed to identify differentially expressed genes. Molecular Complex Detection (MCODE) was used to identify significant gene modules among upregulated genes, and univariate Cox regression analyses assessed the prognostic value of hub genes. Retrospective qPCR was conducted on tissue and plasma samples from KIRC patients to validate findings. Single-cell sequencing data from the GSE159115 dataset were analyzed, and the CIBERSORT algorithm was applied to evaluate the composition of tumor immune infiltrating cells (TIICs).ResultsCENPF was identified as a hub gene significantly upregulated in renal cancer subtypes, with overexpression linked to worse survival outcomes in KIRC patients. Retrospective qPCR confirmed high CENPF expression was associated with poorer prognosis. Single-cell sequencing revealed that CENPF is predominantly expressed in T-cell clusters. TIIC analysis showed a negative correlation between CENPF and resting mast cells, but positive correlations with follicular helper T-cells and memory-activated CD4T-cells. Prognostic analysis indicated that high follicular helper T-cell expression predicted poorer survival, while high plasma cell expression correlated with better outcomes.ConclusionCENPF plays a critical role in tumor progression and the modulation of the tumor immune microenvironment in KIRC. These findings suggest that CENPF could serve as a valuable prognostic biomarker and potential target for therapeutic intervention in renal cancer.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251330791"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}